AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS RCEL 深 沪
已收盘 07-18 16:00:00 美东时间
5.17
-0.260
-4.79%
华盛通- 最 高5.85
- 今 开5.50
- 成交量 43.47万股
- 最 低 5.0327
- 昨 收 5.43
- 总市值 1.37亿
- 52周最高 14.16
- 市盈率 静 --
- 换手率 1.64%
- 52周最低 4.71
- 委 比 52.55%
- 总股本 2643.47万
- 历史最高 49.11
- 量 比 1.87
- 振 幅 15.05%
- 历史最低 4.41
- 每 手 1
- 风险率 3.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold stocks in the health care sector presents an opportunity to b...
06-26 20:15
AVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL
AVITA Medical highlights data showing reduced hospital stay for burn patients treated with its RECELL technology, supported by a study analyzing over 6,300 patients. The spray-on skin cell therapy reduces hospital stays by 6.2 days (35.7%) and saves $300 million over five years compared to traditional grafting. The study underscores RECELL’s clinical and economic benefits, with the technology used in over 130 U.S. burn centers.
06-09 13:00
美股大行评级 | 潜在涨幅925.64%！Aemetis获Ascendiant Capital升目标价至20美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1138028221594226688.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Aemetis(AMTX)"买入"评级，目标价从19美元升至20美元</p> <p>• Ascendiant Capital：维持Lucid Diagnostics(LUCD)"买
06-07 08:37
D. Boral Capital Maintains Buy on AVITA Medical, Maintains $19 Price Target
D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:RCEL) with a Buy and maintains $19 price target.
06-06 19:13
AVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™
AVITA Medical announced the first clinical publication on Cohealyx, a collagen-based dermal matrix, in the *Journal of Surgery*. The study, conducted at The Ohio State University Wexner Medical Center, showed that Cohealyx achieved autograft readiness in 5 to 10 days, significantly faster than the typical 2 to 4 weeks. Two patients with complex hand wounds saw excellent outcomes, with one ready for autografting by day 7 and the other by day 13. C...
06-05 20:04
AVITA Medical’s RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards
AVITA Medical's RECELL system, including RECELL GO, has been awarded "Best New Technology Solution – Surgical" in the 2025 MedTech Breakthrough Awards. FDA-approved for burn wounds and skin defects, RECELL treats over 30,000 patients globally, requiring less donor skin, reducing pain, and improving recovery. RECELL GO enhances procedural consistency and team coordination. CEO Jim Corbett highlighted the technology's benefits, including faster hea...
06-04 00:00
Avita Medical Updates Bylaws for Governance Enhancement
Avita Medical ( ($RCEL) ) has provided an announcement. Avita Medical, Inc. rec...
05-16 05:22
AVITA Medical Affirms FY2025 Commercial Revenue Guidance of $100.00M-$106.00M vs $102.26M Est
AVITA Medical (NASDAQ:RCEL) affirms FY2025 sales outlook from $100.00 million-$106.00 million to $100.00 million-$106.00 million vs $102.26 million estimate.
05-09 06:50
Avita Medical shares are trading lower after the company reported worse-than-expected Q1 financial results.
Avita Medical shares are trading lower after the company reported worse-than-ex...
05-09 04:45
AVITA Medical Q1 EPS $(0.53) Misses $(0.39) Estimate, Sales $18.51M Miss $21.14M Estimate
AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.39) by 35.9 percent. This is a 27.4 percent increase over losses of $(0.73) per share from the
05-09 04:04
